IDEAYA Biosciences, Inc.IDYANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank32
3Y CAGR-25.4%
5Y CAGR-26.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-25.4%/yr
vs +127.6%/yr prior
5Y CAGR
-26.5%/yr
Consistent
Acceleration
-153.1pp
Decelerating
Percentile
P32
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.34% |
| Q3 2025 | 11.81% |
| Q2 2025 | 4.71% |
| Q1 2025 | -49.43% |
| Q4 2024 | 145.28% |
| Q3 2024 | 4.80% |
| Q2 2024 | 27.40% |
| Q1 2024 | 10.41% |
| Q4 2023 | 15.04% |
| Q3 2023 | 15.50% |
| Q2 2023 | 4.73% |
| Q1 2023 | 12.73% |
| Q4 2022 | 10.47% |
| Q3 2022 | -1.86% |
| Q2 2022 | 15.97% |
| Q1 2022 | 22.02% |
| Q4 2021 | 3.91% |
| Q3 2021 | 3.50% |
| Q2 2021 | 29.51% |
| Q1 2021 | -4.02% |
| Q4 2020 | 20.22% |
| Q3 2020 | 16.61% |
| Q2 2020 | -4.76% |
| Q1 2020 | 5.68% |
| Q4 2019 | -4.28% |
| Q3 2019 | 0.72% |
| Q2 2019 | 10.79% |
| Q1 2019 | 5.53% |
| Q4 2018 | -39.57% |
| Q3 2018 | 94.93% |
| Q2 2018 | 23.64% |
| Q1 2018 | 0.00% |